Impact of type 2 diabetes mellitus on the TNM classification of kidney cancer Repercusión de la diabetes tipo 2 en la clasificación TNM de pacientes con cáncer renal Academic Article in Scopus uri icon

abstract

  • © 2018 Elsevier Doyma Mexico. All rights reserved.OBJECTIVE: To evaluate the influence of type 2 diabetes mellitus on the TNM staging classification in patients with renal cell carcinoma treated through nephrectomy. MATERIALS AND METHODS: A retrospective, cross-sectional, descriptive study was conducted. The case records were reviewed of patients with sporadic and unilateral renal cell carcinoma that underwent nephrectomy at the Urology Department of the Hospital Metropolitano Dr. Bernardo Sepúlveda. Demographic and clinical variables: age, sex, pathologic tumor size, and type of surgery (radical or partial). The comorbidities evaluated were high blood pressure, type 2 diabetes mellitus, and dyslipidemia. Staging and tumor size (2009 TNM classification), Fuhrman grade, and histologic type were analyzed. Each TNM classification result was analyzed independently through the c2 test. Overall survival and recurrence-free survival were evaluated through the Kaplan-Meier test. RESULTS: A total of 18.6% of the 43 study patients presented with type 2 diabetes mellitus. T1b tumors predominated in 32.6% of the cases. No statistically significant differences were found in the comparison of pathologic tumor stage (p = 0.5), lymph node disease (p = 0.7), or metastasis (p = 0.5) between patients with and without diabetes. Median follow-up was 45 months and no differences were found in the comparison of overall survival and recurrence-free survival in the patients with type 2 diabetes mellitus (p = 0.76) and those without the pathology (p = 0.78). CONCLUSIONS: Type 2 diabetes mellitus had no significant impact on the pathologic stage of renal cell carcinoma or on overall survival and recurrence-free survival in those patients.

publication date

  • January 1, 2018